Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1978 June; 61(6): 1683–1690.
PMCID: PMC372695

Methscopolamine Inhibition of Sleep-Related Growth Hormone Secretion



We have examined the effects of cholinergic blockade with 0.5 mg methscopolamine bromide, intramuscularly, on sleep-related and insulin-induced growth hormone (GH) secretion. 17 normal young men were studied; 8 had sleep studies, and 12 (including 3 who also had sleep studies) had insulin tolerance tests (ITT) with 0.1 U/kg of regular insulin. After an adjustment night in the sleep laboratory, saline control night and methscopolamine night studies were done in random sequence; study procedures included electroencephalographic, electromyographic, and electrooculographic recordings, and blood sampling every 20 min for hormone radioimmunoassays. Prolactin levels were also measured during sleep. For methscopolamine night studies, the mean overall control GH level of 2.89±0.44 ng/ml and the mean peak control GH level of 11.09±3.11 ng/ml were dramatically reduced to 0.75±0.01 and 1.04±0.25 ng/ml, respectively (P<0.0001 and <0.001). Despite virtual absence of GH secretion during the night in every study subject, no measured sleep characteristic was affected by methscopolamine, including total slow-wave sleep (12.1±2.6% control vs. 10.3±2.5% drug, P>0.2). Sleep prolactin levels were not changed by methscopolamine. In contrast to the abolition of sleep-related GH secretion, administration of methscopolamine had only a marginal effect on the GH response to insulin hypoglycemia. None of nine time points differed significantly, as was also the case with peak levels, mean increments, and areas under the curves (P>0.2). Analysis of variance did, however, indicate that the lower GH concentrations achieved during ITT after methscopolamine (average 31.7% below control) were significantly different than control concentrations. We conclude that the burst of GH secretion which normally occurs after sleep onset is primed by a cholinergic mechanism which does not influence slow-wave sleep. Cholinergic mechanisms do not appear to play an important role in sleep-related prolactin secretion. The contrast between the complete suppression of sleep-related GH release and the relatively small inhibitory effect on ITT-induced GH secretion suggests that the neurotransmitter mechanisms, and presumably the pathways, which subserve sleep-related GH secretion in man may be different from those which mediate the GH response to pharmacologic stimuli such as insulin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest. 1968 Sep;47(9):2079–2090. [PMC free article] [PubMed]
  • Honda Y, Takahashi K, Takahashi S, Azumi K, Irie M, Sakuma M, Tsushima T, Shizume K. Growth hormone secretion during nocturnal sleep in normal subjects. J Clin Endocrinol Metab. 1969 Jan;29(1):20–29. [PubMed]
  • Parker DC, Sassin JF, Mace JW, Gotlin RW, Rossman LG. Human growth hormone release during sleep: electroencephalographic correlation. J Clin Endocrinol Metab. 1969 Jun;29(6):871–874. [PubMed]
  • Sassin JF, Frantz AG, Weitzman ED, Kapen S. Human prolactin: 24-hour pattern with increased release during sleep. Science. 1972 Sep 29;177(4055):1205–1207. [PubMed]
  • Parker DC, Rossman LG, Vander Laan EF. Sleep-related, nychthermeral and briefly episodic variation in human plasma prolactin concentrations. J Clin Endocrinol Metab. 1973 Jun;36(6):1119–1124. [PubMed]
  • Parker DC, Rossman LG, Vanderlaan EF. Relation of sleep-entrained human prolactin release to REM-nonREM cycles. J Clin Endocrinol Metab. 1974 Apr;38(4):646–651. [PubMed]
  • Mendelson WB, Jacobs LS, Reichman JD, Othmer E, Cryer PE, Trivedi B, Daughaday WH. Suppression of sleep-related prolactin secretion and enhancement of sleep-related growth hormone secretion. J Clin Invest. 1975 Sep;56(3):690–697. [PMC free article] [PubMed]
  • Sassin JF, Frantz AG, Kapen S, Weitzman ED. The nocturnal rise of human prolactin is dependent on sleep. J Clin Endocrinol Metab. 1973 Sep;37(3):436–440. [PubMed]
  • VanderLaan WP, Parker DC, Rossman LG, VanderLaan EF. Implications of growth hormone release in sleep. Metabolism. 1970 Oct;19(10):891–897. [PubMed]
  • Parker DC, Rossman LG. Human growth hormone release in sleep: nonsuppression by acute hyperglycemia. J Clin Endocrinol Metab. 1971 Jan;32(1):65–69. [PubMed]
  • Lucke C, Glick SM. Experimental modification of the sleep-induced peak of growth hormone secretion. J Clin Endocrinol Metab. 1971 Jun;32(6):729–736. [PubMed]
  • Schnure JJ, Raskin P, Lipman RL. Growth hormone secretion during sleep: impairment in glucose tolerance and nonsuppressibility by hyperglycemia. J Clin Endocrinol Metab. 1971 Aug;33(2):234–241. [PubMed]
  • Lucke C, Glick SM. Effect of medroxyprogesterone acetate on the sleep induced peak of growth hormone secretion. J Clin Endocrinol Metab. 1971 Nov;33(5):851–853. [PubMed]
  • Perlow M, Sassin J, Boyar R, Hellman L, Weitzman ED. Reduction of growth hormone secretion following clomiphene administration. Metabolism. 1973 Oct;22(10):1269–1275. [PubMed]
  • Chihara K, Kato Y, Maeda K, Matsukura S, Imura H. Suppression by cyproheptadine of human growth hormone and cortisol secretion during sleep. J Clin Invest. 1976 Jun;57(6):1393–1402. [PMC free article] [PubMed]
  • Parker DC, Rossman LG, Siler TM, Rivier J, Yen SS, Guillemin R. Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin. J Clin Endocrinol Metab. 1974 Mar;38(3):496–499. [PubMed]
  • Lipman RL, Taylor AL, Schenk A, Mintz DH. Inhibition of sleep related growth hormone release by elevated free fatty acids. J Clin Endocrinol Metab. 1972 Oct;35(4):592–594. [PubMed]
  • Quabbe HJ, Helge H, Kubicki S. Nocturnal growth hormone secretion: correlation with sleeping EEG in adults and pattern in children and adolescents with non-pituitary dwarfism, overgrowth and with obesity. Acta Endocrinol (Copenh) 1971;67(4):767–783. [PubMed]
  • Othmer E, Levine WR, Malarkey WB, Corvalan JC, Hayden-Otto MP, Fishman PM, Daughaday WH. Body build and sleep-related growth hormone secretion. Horm Res. 1974;5(3):156–166. [PubMed]
  • Carlson HE, Gillin JC, Gorden P, Snyder F. Abscence of sleep-related growth hormone peaks in aged normal subjects and in acromegaly. J Clin Endocrinol Metab. 1972 Jun;34(6):1102–1105. [PubMed]
  • Powell GF, Hopwood NJ, Barratt ES. Growth hormone studies before and during catch-up growth in a child with emotional deprivation and short stature. J Clin Endocrinol Metab. 1973 Nov;37(5):674–679. [PubMed]
  • Rubin RT, Gouin PR, Arenander AT, Poland RE. Human growth hormone release during sleep following prolonged flurazepam administration. Res Commun Chem Pathol Pharmacol. 1973 Jul;6(1):331–334. [PubMed]
  • Sinha YN, Selby FW, Lewis UJ, VanderLaan WP. A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab. 1973 Mar;36(3):509–516. [PubMed]
  • Herington AC, Jacobs LS, Daughaday WH. Radioreceptor and radioimmunoassay quantitation of human growth hormone in acromegalic serum: overestimation by immunoassay and systematic differences between antisera. J Clin Endocrinol Metab. 1974 Aug;39(2):257–262. [PubMed]
  • Domino EF, Corssen G. Central and peripheral effects of muscarinic cholinergic blocking agents in man. Anesthesiology. 1967 May-Jun;28(3):568–574. [PubMed]
  • Malick JB, Barnett A. Central versus peripheral anticholinergic activity as assessed by two in vivo procedures in mice. J Pharm Sci. 1975 Jun;64(6):1066–1068. [PubMed]
  • Donoso AO, Bacha JC. Role of the blood-brain barrier in the anticholinergic differential effects on LH and prolactin release in proestrous rats. J Neural Transm. 1975;37(2):155–164. [PubMed]
  • Granacher RP, Baldessarini RJ. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry. 1975 Mar;32(3):375–380. [PubMed]
  • Salvadorini F, Galeone F, Nicotera M, Ombrato M, Saba P. Clinical evaluation of CDP-choline (Nicholin): efficacy As antidepressant treatment. Curr Ther Res Clin Exp. 1975 Sep;18(3):513–520. [PubMed]
  • Sagales T, Erill S, Domino EF. Differential effects of scopolamine and chlorpromazine on REM and NREM sleep in normal male subjects. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):522–529. [PubMed]
  • Grandison L, Gelato M, Meites J. Inhibition of prolactin secretion by cholinergic drug. Proc Soc Exp Biol Med. 1974 Apr;145(4):1236–1239. [PubMed]
  • Libertun C, McCann SM. Further evidence for cholinergic control of gonadotropin and prolactin secretion. Proc Soc Exp Biol Med. 1974 Nov;147(2):498–504. [PubMed]
  • McLean BK, Nikitovitch-Winer MB. Cholinergic control of the nocturnal prolactin surge in the pseudopregnant rat. Endocrinology. 1975 Oct;97(4):763–770. [PubMed]
  • Grandison L, Meites J. Evidence for adrenergic mediation of cholinergic inhibition of prolactin release. Endocrinology. 1976 Sep;99(3):775–779. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation